Google
TRAX — FIRST TRACKS BIOTHERAPEUTICS (Healthcare >> Biotechnology)
TRAX FAQ
What is TRAX's ROE?
FIRST TRACKS BIOTHERAPEUTICS reports a Return on Equity (ROE) of -37.94%.
What is TRAX's dividend yield?
FIRST TRACKS BIOTHERAPEUTICS offers a dividend yield of 0.00%.
What is TRAX's Deepscope Quality Score?
Deepscope rates TRAX's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy TRAX?
Deepscope's AI Timing Score for TRAX is 29 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does TRAX belong to?
FIRST TRACKS BIOTHERAPEUTICS is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 15.75
Price
-0.85
(-5.12%)
Day Change
|
|
|---|
TRAX, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 15.75 |
| PBV / Sector |
2.25 / 4.75
|
| Earning Per Share | -2.66 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
7.94 M
|
| Average 1W Daily Value |
10.63 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-09 09:40:12 |
| Symbol | TRAX |
| Name | FIRST TRACKS BIOTHERAPEUTICS |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 34.89 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 579.21 / 9,000.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121
Phone: 858 362 6295
Website: https://www.firsttracksbio.com
Employees: 104
Sector: Healthcare >> Biotechnology
Description: First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
